Medimaps Group Launches Next-Generation TBS Osteo Software Across Europe to Revolutionize Osteoporosis Detection
Medimaps Group S.A., a Swiss-based global leader in AI-powered bone health solutions, has announced the European launch of its next-generation TBS Osteo Advanced software, following its recent debut in the United States. With clearance under the EU’s Medical Device Regulation (MDR), the rollout marks a significant step forward in transforming osteoporosis detection and enhancing bone health management throughout Europe.
The new software is designed to analyze Trabecular Bone Score (TBS) — a metric that evaluates bone microarchitecture, offering deeper insights beyond traditional bone mineral density (BMD) scans. The latest iteration of TBS Osteo introduces sophisticated advancements, including enhanced correction for soft tissue thickness situated anterior to the lumbar spine. This feature improves diagnostic accuracy by ensuring TBS assessments are inclusive of a wider array of patient body types, making the software a more equitable solution for clinical practice.
In addition to improved patient assessment capabilities, TBS Osteo Advanced includes new centralized system management tools. These allow hospitals and large healthcare networks to manage TBS software across multiple dual-energy X-ray absorptiometry (DXA) systems. By enabling centralized oversight and standardized workflows across locations, the software enhances operational efficiency and ensures consistent care delivery, especially important for radiology departments operating within complex healthcare systems.
Medimaps is also offering the new version via a flexible subscription model. This approach gives customers continuous access to software updates, newly released features, and technical support. Current users of TBS Osteo are eligible to upgrade to the new advanced version, allowing them to adopt the latest features without overhauling their existing infrastructure.
“The next-generation TBS Osteo software has been developed with the needs of today’s radiology professionals in mind,” said Univ. Prof. Dr. Didier Hans, CEO and Co-founder of Medimaps Group. “It maximizes clinical output while minimizing logistical burden. Fully integrated into the clinical workflow and performed at the time of the DXA scan, TBS Osteo delivers a complete report within seconds — combining BMD and other critical clinical factors. This elevates our software beyond the current standard of care.”
Hans added that many leading hospitals globally — including top medical centers in the U.S. — have adopted TBS Osteo alongside DXA scanning, positioning the technology as the gold standard in bone health monitoring.
Since its initial launch in 2012, TBS Osteo has become widely adopted in clinical practice worldwide, supported by more than 1,400 peer-reviewed publications. The software is referenced in over 30 national and international clinical guidelines, including those focused on osteoporosis assessment and fracture risk management. Its scientific rigor and regulatory recognition have helped it achieve a unique status: in Europe, it remains the only approved medical software for assessing bone microarchitecture in routine clinical settings.
The launch of the advanced TBS Osteo platform in Europe comes at a critical time, as the prevalence of osteoporosis continues to rise. This chronic skeletal disorder weakens bones and increases the risk of fragility fractures — particularly among older adults. These fractures often result in significant disability, reduced quality of life, and increased mortality, placing a tremendous burden on patients, families, and healthcare systems.
According to the International Osteoporosis Foundation, roughly 32 million people aged 50 and above across Europe are currently living with osteoporosis. The number of osteoporotic fractures in the European Union, Switzerland, and the United Kingdom is projected to increase dramatically — from 4.33 million in 2019 to 5.34 million by 2034, representing an annual surge of over 1 million fractures. Despite the availability of effective pharmacological treatments, only about 1 in 5 patients who suffer an osteoporotic fracture are appropriately diagnosed or treated, revealing a major care gap.
By offering more accurate and scalable diagnostic tools like TBS Osteo Advanced, Medimaps aims to close this care gap and promote earlier detection, improved risk stratification, and timely intervention for patients at risk of fractures. The integration of advanced imaging software into standard DXA assessments enables clinicians to move beyond bone density scores and toward a more holistic view of skeletal health.
